Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Press release

Acarix CPT III Code Removed from United Healthcare Medicare Advantage Noncovered List

Acarix

Acarix, a leader in rapid AI and acoustics-based cardiac diagnostics, announces effective May 1, 2024, that the CADScor System CPT III 0716T code has been officially removed from the United Healthcare Medicare Advantage non-covered list. This important development marks the first step in removing barriers to widespread usage for patients covered by this plan.

"We are thrilled to announce that the CADScor System CPT III 0716T code has been removed from the non-covered list for United Healthcare Medicare Advantage," said Aamir Mahmood, President & CEO of Acarix. "This decision reflects a positive change in patient accessibility. By allowing payment for the test, United Healthcare Medicare Advantage is aligning with the healthcare industry's shift towards value-driven practices, emphasizing quality and efficiency. The CADScor System provides an accurate and non-invasive tool for risk stratification of coronary artery disease at the point of care, enabling clinicians to make decisions, leading to better outcomes and cost-effective care."

For more information contact:
Jennifer Anderson, Head of Marketing & Communications, phone +1 720 471 4625, email jennifer.anderson@acarix.com 

About Acarix

Acarix is a Swedish medical device company that innovates solutions for rapid rule out of coronary artery disease (CAD) at point of care. The CE-approved and FDA DeNovo-cleared Acarix CADScor System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive, and costly diagnostic procedures. The CADScor System has been used on more than 29,000 patients. Acarix recommends CADScor System as a first-line diagnostic aid that uses highly sensitive acoustics and advanced computational processing to analyze coronary blood flow to rule out significant coronary artery disease (CAD), with at least 96% certainty at point of care. Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX). Carnegie Investment Bank is the Certified Advisor of Acarix. For more information, please visit www.acarix.com

Attachments
Acarix CPT III Code Removed from United Healthcare Medicare Advantage Noncovered List

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.